Welcome to our dedicated page for Zentalis Pharmaceuticals SEC filings (Ticker: ZNTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances azenosertib, an investigational WEE1 inhibitor, through clinical development. As a clinical-stage biopharmaceutical issuer, Zentalis files Forms 10-K and 10-Q for annual and quarterly reporting, along with Form 8-K current reports detailing material events related to its oncology programs, financial position and corporate governance.
Recent Form 8-K filings describe financial results and operational progress, including updates on the DENALI Phase 2 trial in Cyclin E1-positive platinum-resistant ovarian cancer (PROC), cash, cash equivalents and marketable securities levels, and the company’s view of its operational runway. Other 8-Ks report leadership and board changes, such as transitions in the Chief Legal Officer and Corporate Secretary role, a director resignation with a corresponding reduction in board size, and a stock repurchase from a major shareholder. These filings often incorporate press releases by reference, providing additional detail on clinical and corporate developments.
Investors can also review disclosures related to stockholder meetings and voting results, such as the annual meeting outcomes for director elections, auditor ratification and advisory votes on executive compensation. Equity compensation arrangements, including inducement stock option grants under the company’s employment inducement incentive award plan, are reported in connection with Nasdaq Listing Rule 5635(c)(4).
On Stock Titan, ZNTL filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how Zentalis’ SEC reports address azenosertib’s clinical status, biomarker-driven strategy, cash resources and governance matters. Users can track new filings in real time as they are posted to EDGAR, and use these insights alongside news and market data to build a more complete picture of Zentalis’ risk profile and development trajectory.
Form 3 initial statement: The reporting person, James B. Bucher, identified his relationship to Zentalis Pharmaceuticals, Inc. as a director and Chief Legal Officer and filed an initial Section 16 Form 3. The filing states no securities are beneficially owned by the reporting person and attaches an exhibit noting a power of attorney. The form is an initial disclosure of ownership status rather than a transaction report.
Zentalis Pharmaceuticals, Inc. reported a leadership transition in its legal function. On August 26, 2025, Andrea Paul notified the Board of her intent to resign as Chief Legal Officer and Corporate Secretary, effective September 18, 2025, to join the partnership of a large international law firm. She will remain a non-executive employee through October 1, 2025.
The company and Ms. Paul expect to enter into a release agreement that will provide payment of her 2025 target annual bonus and continued vesting of her equity awards during a transitional services period, after which certain awards will vest in full. In connection with her resignation, Zentalis appointed James B. Bucher as its new Chief Legal Officer and Corporate Secretary, effective September 18, 2025. The company describes Mr. Bucher as a seasoned life sciences legal executive with extensive public company and strategic transaction experience.
Zentalis Pharmaceuticals (ZNTL) Director Luke Nathaniel Walker received a grant of 57,603 restricted stock units (RSUs) on June 17, 2025, as part of the company's Non-Employee Director Compensation Program. Following this transaction, Walker's direct ownership increased to 144,284 shares.
Key details of the RSU grant:
- Each RSU represents a contingent right to receive one share of common stock
- Vesting occurs at the earlier of June 17, 2026, or the next annual stockholder meeting
- Vesting is contingent on continued service on the Board of Directors
- The RSUs were granted at $0 cost to the director
The transaction was reported via Form 4 filing and was executed through an attorney-in-fact, Andrea Paul, on June 18, 2025. This equity grant aligns with standard director compensation practices and serves to strengthen the alignment between director and shareholder interests.
Zentalis Pharmaceuticals (ZNTL) Director Jan Skvarka received a grant of 57,603 restricted stock units (RSUs) on June 17, 2025, as part of the company's Non-Employee Director Compensation Program. Following this transaction, Skvarka now beneficially owns 207,154 shares directly.
Key details of the RSU grant:
- Each RSU represents a contingent right to receive one share of common stock
- Vesting occurs at the earlier of June 17, 2026 or the next annual stockholder meeting
- Vesting is contingent on continued service on the Board of Directors
- The RSUs were granted at $0 exercise price
This Form 4 filing was submitted by Andrea Paul as attorney-in-fact for Jan Skvarka on June 18, 2025, in compliance with SEC insider trading reporting requirements.
Zentalis Pharmaceuticals (ZNTL) Director David Michael Johnson reported acquiring 57,603 restricted stock units (RSUs) on June 17, 2025. The RSUs were granted under the company's Non-Employee Director Compensation Program at a price of $0.
Key details of the transaction:
- Following the transaction, Johnson directly owns 250,421 shares
- The RSUs will vest on the earlier of June 17, 2026 or the next annual stockholder meeting
- Vesting is contingent on Johnson's continued service on the Board of Directors
- Each RSU represents the right to receive one share of common stock upon vesting
The Form 4 was filed on June 28, 2025, with the signature executed by Andrea Paul as attorney-in-fact for David M. Johnson on June 18, 2025.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) held its 2025 Annual Meeting of Stockholders on June 17, with 80.9% of outstanding shares represented. Key voting results include:
- Director Elections: Three Class II directors were elected to serve until 2028: - Scott Myers (43M votes for) - Karan Takhar (30.7M votes for) - Luke Walker, M.D. (36.6M votes for)
- Auditor Ratification: Ernst & Young LLP appointment was approved with overwhelming support (58.1M votes for, representing 99.8% approval)
- Executive Compensation: The "Say-on-Pay" vote passed but with significant opposition - 62.9% in favor (29.5M votes) versus 37.1% against (17.4M votes), indicating substantial shareholder concerns about executive compensation practices
The meeting results suggest strong shareholder engagement but reveal notable dissent regarding executive compensation and varying levels of support for board nominees, particularly for Karan Takhar who received the lowest approval rate among directors.